Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

Raymond, Éric; Niccoli, Patricia; Raoul, Jean-Luc; Bang, Yeonghak; Borbath, Ivan; Lombard‐Bohas, Catherine; Valle, J. W.; Metrakos, Peter; Smith, Denis; Ai, Vinik; Chen, J.; Hoersch, Dieter; Castellano, Daniel; Kennecke, H.; Picus, Joel; Hazel, G. Van; Donghui, LU; Chao, Richard C.; Patyna, Shem; Cutsem, Éric Van

doi:10.1200/jco.2011.29.15_suppl.4008

Cited by 24 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…101 A large proportion of patients on the placebo arm subsequently received sunitinib at progression, and no significant difference in overall survival was observed between the arms. 102 Adverse events associated with sunitinib include fatigue and, in rare cases, congestive heart failure. 103 Other side effects have also been described.…”

Section: Management Of Locoregional Unresectable And/or Metastatic Nementioning

confidence: 99%

Neuroendocrine Tumors

Kulke

Benson²,

Bergsland

et al. 2012

J Natl Compr Canc Netw

166

127

View full text Add to dashboard Cite

Neuroendocrine tumors comprise a broad family of tumors, the most common of which are carcinoid and pancreatic neuroendocrine tumors. The NCCN Neuroendocrine Tumors Guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine tumors. Most of the recommendations pertain to well-differentiated, low- to intermediate-grade tumors. This updated version of the NCCN Guidelines includes a new section on pathology for diagnosis and reporting and revised recommendations for the surgical management of neuroendocrine tumors of the pancreas.

show abstract

Section: Management Of Locoregional Unresectable And/or Metastatic Nementioning

confidence: 99%

Neuroendocrine Tumors

Kulke

Benson²,

Bergsland

et al. 2012

J Natl Compr Canc Netw

166

127

View full text Add to dashboard Cite

show abstract

“…The study exhibited some weaknesses including low recruitment (50% of preplanned patients), low number of patients at risk beyond 10 months, high death rate indicating inclusion of highly advanced patients, and lack of central radiology. The initially reported survival benefit was not evident with further follow-up (Raymond et al 2011b). Most frequent side effects included diarrhea (59%), nausea (45%), asthenia (34%), and vomiting (34%).…”

Section: Molecular Targets In Gep-nensmentioning

confidence: 99%

Neuroendocrine tumor disease: an evolving landscape

Frilling

Åkerström

Falconi

et al. 2012

Endocrine-Related Cancer

147

106

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a heterogenous group of tumors arising from a variety of neuroendocrine cell types. The incidence and prevalence of GEPNENs have markedly increased over the last three decades. Symptoms are often absent in early disease, or vague and nonspecific even in advanced disease. Delayed diagnosis is thus common. Chromogranin A is the most commonly used biomarker but has limitations as does the proliferative marker Ki-67%, which is often used for tumor grading and determination of therapy. The development of a multidimensional prognostic nomogram may be valuable in predicting tumor behavior and guiding therapy but requires validation. Identification of NENs that express somatostatin receptors (SSTR) allows for SSTR scintigraphy and positron emission tomography imaging using novel radiolabeled compounds. Complete surgical resection of limited disease or endoscopic ablation of small lesions localized in stomach or rectum can provide cure; however, the majority of GEP-NENs are metastatic (most frequently the liver and/or mesenteric lymph nodes) at diagnosis. Selected patients with metastatic disease may benefit from advanced surgical techniques including hepatic resection or liver transplantation. Somatostatin analogs are effective for symptomatic treatment and exhibit some degree of antiproliferative activity in small intestinal NENs. There is a place for streptozotocin, temozolomide, and capecitabine in the management of pancreatic NENs, while new agents targeting either mTOR (everolimus) or angiogenic (sunitinib) pathways have shown efficacy in these lesions.

show abstract

“…110 By contrast, the differences in overall survival have not reached statistical significance in the trial update. Nevertheless, the results were encouraging and the FDA approved sunitinib as yet another option for patients with unresectable, locally advanced or metastatic PanNETs.…”

Section: Therapeutic Advancesmentioning

confidence: 98%

Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy

Wilde

Edil

Hruban

et al. 2012

Nat Rev Gastroenterol Hepatol

105

View full text Add to dashboard Cite

Well-differentiated pancreatic neuroendocrine tumors (PanNETs) comprise ~1–3% of pancreatic neoplasms. Although long considered as reasonably benign lesions, PanNETs have considerable malignant potential, with a 5-year survival of ~65% and a 10-year survival of 45% for resected lesions. As PanNETs have a low incidence, they have been understudied, with few advances made until the completion of their exomic sequencing in the past year. In this Review, we summarize some of the latest insights into the genetics of PanNETs, and their probable implications in the context of prognosis and therapy. In particular, we discuss two genes (DAXX and ATRX) that have collectively been identified as mutated in >40% of PanNETs, and the biological and prognostic implications of these novel mutations. The identification of recurrent somatic mutations within the mTOR signaling pathway and the therapeutic implications for personalized therapy in patients with PanNETs are also discussed. Finally, this Review outlines state-of-the-art advances in the biology of PanNETs that are of emerging translational importance.

show abstract

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

Cited by 24 publications

References 0 publications

Neuroendocrine Tumors

Neuroendocrine Tumors

Neuroendocrine tumor disease: an evolving landscape

Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy

Contact Info

Product

Resources

About